Pharmaceutical giant Novo Nordisk has unveiled a new subscription service aimed at providing patients with a more predictable and lower monthly cost for its popular GLP-1 weight-loss medication, Wegovy. This initiative seeks to encourage long-term adherence to therapy, according to company executives.

Significant Annual Savings Announced

The new program, which began on Tuesday, March 31, offers substantial savings for self-pay customers without traditional insurance coverage. Patients opting for a 12-month subscription could save up to $1,200 annually for the Wegovy injection.

Jamey Millar, Executive Vice President of U.S. Operations for Novo Nordisk, stated that the subscription model is designed to help patients remain consistent with their treatment over time. The program is currently accessible through telehealth providers Ro, WeightWatchers, and LifeMD, with others like Hims & Hers and Sesame slated to join soon.

Expert Perspective on Affordability

Dr. Jorge Moreno, an obesity specialist at Yale Medicine, noted that approximately 20-25% of his patients currently cover the cost of GLP-1 drugs entirely out-of-pocket due to inconsistent insurance coverage. He suggested the plan could assist these individuals, provided they can manage the commitment of paying around $250 monthly.

Dr. Moreno cautioned that any actual savings might be offset by required membership fees for certain telehealth platforms. He emphasized the importance for new subscribers to understand the terms regarding cancellations, side effects, and potential refunds.

Understanding Wegovy and Semaglutide

Wegovy is the formulation of the drug semaglutide specifically approved for weight management. This active ingredient functions by mimicking a natural hormone produced after eating, which subsequently reduces appetite and enhances feelings of fullness, thereby aiding weight loss.

It is important to note that Wegovy shares the same active ingredient, semaglutide, as Ozempic, which is approved for diabetes management.

Detailed Pricing Structure Under Subscription

Current self-pay rates without a subscription are $345 monthly for the Wegovy pen and $299 for the pill, as reported by Novo Nordisk.

Wegovy Injection Subscription Costs (Pen)

  • 3-Month Plan: $329 per month ($240 annual savings).
  • 6-Month Plan: $299 per month ($600 annual savings).
  • 12-Month Plan: $249 per month ($1,200 annual savings).

The price for the injection remains constant regardless of the specific dose required by the patient.

Wegovy Pill Subscription Costs (9mg and 25mg Doses)

  • 3-Month Plan: $289 per month ($120 annual savings).
  • 6-Month Plan: $269 per month ($360 annual savings).
  • 12-Month Plan: $249 per month ($600 annual savings).

Millar expressed optimism that cash prices for the medication will continue to decrease over time as the program matures.